Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03101644

Optimization of Darunavir Therapy and Dosage Recommendations

Human Immunodeficiency Virus I Infection Clinical Trial

Official title:
Optimization of Darunavir Therapy Through Population Pharmacokinetic Modeling, Simulations and Dosage Guidelines

Clinical Trial Summary

This study will assess and characterize the variability observed in the response to darunavir therapy, an antiretroviral medication used against the Human Immunodeficiency Virus (HIV). More specifically, it aims to quantify variations in the drug's blood concentrations and determine the sources of such variability, both genetic and non-genetic. In light of this information, current dosage guidelines will then be reviewed.

Clinical Trial Description

Data will be used to create a population pharmacokinetic model. Inter- and intra-individual pharmacokinetic variability will be quantified and linked to patient-specific covariates, both genetic and non-genetic in nature. Pharmacokinetic-pharmacodynamic relationships will be established, linking drug exposure to efficacy (as measured by CD4 cell count and viral load reduction) and toxicity (as measured by frequency and degree of adverse events). Simulations will be conducted for specific patient profiles and current dosage guidelines reviewed.

Pharmacokinetic design : combined sparse/intensive sampling

- Sparse sampling : One blood sample collected in each individual at a random post-intake time (during a routine visit to the hospital), up to three times over the course of the study period (months 1-18).

- Intensive sampling : Eight blood samples collected over six hours in a subset of twelve individuals (during an additional observation period, months 19-22). ;

Study Design

Related Conditions & MeSH terms

  • Acquired Immunodeficiency Syndrome
  • HIV Infections
  • Human Immunodeficiency Virus I Infection
Clinical Trial Details
NCT number NCT03101644
Study type Interventional
Source Université Catholique de Louvain
Contact
Status Completed
Phase Phase 4
Start date March 23, 2017
Completion date June 12, 2019
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05261191 - A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy Phase 1
Completed NCT01381029 - Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals
Recruiting NCT05031819 - Managing Hypertension Among People Living With HIV N/A
Recruiting NCT04132674 - Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed Phase 4
Not yet recruiting NCT01541631 - A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes N/A
Not yet recruiting NCT06368453 - A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test N/A
Completed NCT01304186 - An Automated, Tailored Information Application for Medication Health Literacy N/A
Active, not recruiting NCT06253533 - ICVAX as a HIV Therapeutic DNA Vaccine Phase 1
Completed NCT03262441 - MMF for HIV Reservoir Reduction Phase 2
Terminated NCT05219916 - Selection of Farnesoid X Receptor (FXR) Ligands on the Reactivation of Latent HIV Proviruses N/A